The KEYNOTE 756 and Checkmate 7FL trials will help clarify the potential benefit of adding single agent anti-PD-1 checkpoint blockade to NACT for patients with high-risk HR+/HER2-negative, Stage II/III breast cancer [8, 9]. Here, ERBB2 is linked to breast cancer.